
The controversial new Alzheimer’s drug Aduhelm is creating something of a civil war in medicine, as health networks, hospitals, insurers and individual doctors weigh impending discussions with patients about whether they should take the medication. Many doctors believe the U.S. Food and Drug Administration “moved the goalposts” to approve Aduhelm (aducanumab) in early June, and… read on > read on >